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ABSTRACT

Author: Zuponcic, Jessica, L. MSABE
Institution: Purdue University
Degree Received: August 2017
Title: Novel Polymer/Bioactive Glass Composites for Bone Regenerative Engineering
Major Professor: Meng Deng
Bone-grafting procedures are necessary when injury to the bone, due to trauma or
disease, surpasses the bone’s ability to auto-repair. These injuries are known as criticalsized defects. Using graft material from the patient’s own body, autografting, risks donor
site morbidity and is size-limited [1, 2]. Using graft material from a donor or cadaver,
allografting, carries some risk of disease transmission and availability is insufficient to
meet demand [1]. These challenges have necessitated the development and use of bone
graft substitutes which, ideally, can match the structural and mechanical properties of
native bone and promote osteogenic differentiation of host cells – leading to new bone
formation. Calcium and phosphate ions, which promote osteogenic differentiation (a
property known as osteoinductivity), can be released from implanted bone grafts by
incorporating bioactive glasses [3]. In this study, porous biomimetic composite scaffolds
were fabricated from poly(lactide-co-glycolide) and a novel bioactive silicate glass. It
was hypothesized that this combination these materials would merge the poly(lactide-coglycolide) mechanical properties with the ion-releasing, osteoinductive properties of the
novel bioactive silicate glass. The scaffolds were optimized for bioactive silicate glass
content, and they demonstrated compressive properties in the mid-range of trabecular
bone. Human mesenchymal stem cells adhered and grew on the composite scaffolds
during in vitro cell culture. Alkaline phosphatase activity was significantly increased on
the composite scaffolds compared to control poly(lactide-co-glycolide) scaffolds – this
resulted in enhanced scaffold mineralization. These experiments supported the promise
of developing osteoinductive composite scaffolds for bone regeneration.
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1. INTRODUCTION

Annually in the US, there are more than 6.5 million fractures - with 500,000 of the
resulting treatments requiring a bone graft [1, 4]. Bone-grafting procedures are necessary
when the wound severity surpasses the bone’s ability to auto-repair – known as criticalsized bone defects. Today’s best treatments for critical-sized defects involve autografts:
harvesting a graft from the patient’s body, typically from the iliac crest, and transferring
it to the wound site [1, 2]. Autografting risks morbidity at the donor site and is sizelimited, but autografts retain many ideal bone tissue characteristics - including
osteoconductivity, osteoinductivity, and osteogenicity [2]. For procedures requiring more
material, grafts from donors or cadavers, known as allografts, can be used. To reduce the
risk of rejection and disease transmission, allograft marrow and cellular debris are
removed with fluids and detergents, then grafts are typically irradiated and frozen or
freeze-dried [1, 5]. Post-processing, allograft osteoinductive and mechanical properties
are reduced, and insufficient revascularization or infection contributes to graft failure in
25%-35% of patients [2, 5]. Furthermore, the demand for allografts exceeds supply necessitating a 3rd treatment strategy involving bone graft substitutes such as bone
cements, composite blocks, and gels [1]. 18-20% of procedures require these substitutes
[3] and, like allografts, all these substitutes have little or no osteoinductivity [1].

To augment osteoinductive properties in an allograft or bone-graft substitute,
osteoinductive growth factors, known as bone morphogenetic proteins (BMPs), are often
added at the surgical site [6, 7]. BMPs were discovered when pieces of decalcified bone,
implanted in soft-tissue and bone defect sites of various animal models, prompted
completely new bone formation - populated with host osteoprogenitor cells, stem cells,
and capillaries [8]. The ability of BMPs to trigger bone formation in soft tissues is
potentially very dangerous; excessive application of BMPs at the surgical site may leech
into surrounding soft tissue and form bone ectopically [6, 7, 9]. Despite the risks, BMPs
are often applied in supraphysiological concentrations to sustain their effects –
compensating for the protein’s short half-life [10, 11]. An additional burden on BMP
usage is cost – about $5,000 US per dose [9]. These drawbacks and clinical challenges
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have inspired decades of research to develop bone graft substitutes that can trigger new
bone formation, exhibit bioactivity (bond to surrounding bone in the wound site), allow
host cell infiltration and migration (osteoconductivity), provide suitable mechanical and
load-bearing properties, exhibit biocompatibility, degrade to allow host tissue
replacement, and be cost-effective [2, 12].

One category of materials, bioactive silicate glasses (BSG), has demonstrated some of
these desired properties. Hench et al. developed the early versions of these glasses,
including the commercially available 45S5 formulation (45 mol% SiO 2 , 24.5 mol% CaO,
6 mol% P 2 O 5 and 24.5 mol% Na 2 O) [13, 14]. Subsequent research revealed another
beneficial property of certain BSG formulations – the ability to trigger stem cells to
differentiate towards the osteoblast lineage [3, 15]. Directing osteogenic differentiation
of mesenchymal stem cells (MSCs) presents a promising strategy for bone repair. Our
previous studies have demonstrated the osteoinductive potential of calcium and
phosphate ions, which are released from these glasses, to trigger endogenous MSC-based
BMP-2 production [3]. Thus, bioactive glasses offer an attractive approach for inducing
osteogenic differentiation leading to bone formation due to its ion release capacity.

Increasing the calcium and phosphate content of the BSGs could provide greater ion
dissolution for osteoinductive signaling. Until recently, however, bioactive silicate
glasses with higher than 20 mol% P 2 O 5 content had not demonstrated bioactive
properties [14]. Using a novel phosphate precursor, phytic acid, Dr. Dong Qiu’s lab at
the Chinese Academy of Sciences fabricated sol-gel derived BSGs that maintained
bioactive properties at higher phosphate contents [14]. The novel BSG used in this study
was developed in collaboration with Dr. Dong Qiu’s lab to have greater P 2 O 5 content,
and relatively high CaO content, compared to the commercially available 45S5
formulation and other BSG adaptations – including 58S and S70C30.

The long-term goal of this work is to develop osteomimetic and osteoinductive composite
scaffolds to promote bone regeneration. In this study, a novel 3D osteomimetic
composite porous scaffold was developed by sintering composite microspheres
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comprised of PLGA and a novel bioactive silicate glass (BSG). It was hypothesized that
this combination of PLGA and this novel BSG would synergistically merge the PLGA
mechanical properties with the osteoinductive properties of the novel BSG.
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2. LITERATURE REVIEW

Bone Anatomy and Remodeling
Bone, a composite of organic and inorganic components – collagen and hydroxyapatite
[16], provides several functions in the body. It offers support and protection for organs
and muscles in the body, and it is vital for movement and transportation; however, these
functions impart stresses and damages to bone over time [17, 18]. Processes for bone
repair and remodeling are necessary to keep it functioning over a lifetime. Bone
macrostructure, microstructure, and histology all contribute to understanding these repair
and remodeling processes.

In long bones, there are two characteristic regions: the epiphysis, or ends of the bone, and
diaphysis, or shaft [17]. The visible, compact outer bone is termed cortical bone; beneath
the cortical layer lies a porous bone type called spongy bone or trabecular bone [17].
Trabecular bone fills the epiphysis and lines the diaphysis around a central marrow cavity
[17]. On a microscopic level, cross-sections of cortical bone reveal many mineralized
layers, called lamellae, which form three types of patterns: haversian systems (also called
osteons), interstitial lamellae, and circumferential lamellae [17, 19].

Lamellae in haversian systems are arranged in concentric circles, like a tree trunk, which
surround a central blood vessel; haversian systems vary in diameter from about 50 μm to
a few hundred μm [17, 19]. These osteons traverse the length of long bone – forming
long misshapen cylinders that can branch many times, twist, change cross-sectional area,
migrate radially towards the periosteum or endosteum, and wrap around other haversian
systems [19]. Although they are roughly cylindrical, haversian canals are often covered
with ridges and irregularities which nest with those of neighboring osteons and lamellar
structures; the neighboring haversian systems are interconnected by orthogonal channels,
called Volkmann’s canals, also containing blood vessels [17, 19]. Interstitial lamellae,
another layered pattern, are remnants of partially remodeled haversian systems; they
appear as parallel lines, do not have a central canal, and fill gaps between non-bordering
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osteons [19]. Lastly, the entire outer and inner surfaces of the cortical bone layer are
lined with several continuous concentric lamellae; blood vessels penetrate these layers
via Volkmann’s canals where they branch off and enter the haversian systems and
remaining canal network [17, 19].

During development, endochondral ossification leads to the formation of long bones –
with characteristic, internal trabecular structures. This process begins with condensation
of mesenchymal cells which, upon reaching a critical mass, will undergo chondrification
[20]. After these cells have differentiated to cartilage cells, and produced sufficient
collagen extracellular matrix (ECM), the perichondrium on the outer central section of
the developing bone, will develop a mineralized bone collar, and the chondrocytes in the
center of the bone shaft will hypertrophy [20]. The ECM in the center of the bone will
develop small cavities as the chondrocytes degrade – resulting in wall-structures;
infiltrating osteoprogenitor cells will mineralize these structures to form trabeculae [20].
A growth plate structure, will form where the ends of the growing bone meet the
diaphysis; this plate will be the primary location of bone lengthening until the end of
development [20].

The mechanism of the collagenous ECM mineralization is somewhat unclear, but it is
known that chondrocytes have a crucial role in this process. Chondrocytes, derived from
mesenchymal progenitor condensation, produce extracellular matrix vesicles (or blebs)
which are capable of concentrating calcium and phosphate ions until mineral nucleations
form on the interior membrane wall [20, 21]. Subsequently, the formation of this
mineralized layer will cause the vesicle to rupture - releasing the mineral layer and
concentrated ions amongst the collagenous ECM [20, 21]. The fragment’s charged
surface continues to attract ion deposition from the surrounding extracellular fluid –
driving matrix mineralization [20].

Successful nucleation of calcium phosphate is largely dependent on local concentrations
of ions. In some cases, mineralization can occur on soft tissues – forming ectopic
calcification [21]. These ectopic formations have been observed in cases where a
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patient’s body fluid has abnormally high levels of mineral ions (as caused by lowered
kidney function) or on damaged tissue - where the mechanism may be related to bleb
formation by apoptosing cells [21]. Systemically, typical blood plasma has a calcium ion
concentration of 2.5mM and phosphate ion concentration of 1mM; serum calcium
concentrations above ~2.8mM may lead to symptoms, and concentrations above 3.0mM
are considered critical [22-24]. In contrast, local calcium ion concentrations during bone
remodeling can climb to around 40mM [25]. To regulate blood calcium levels, the body
uses two hormones: parathyroid hormone and calcitonin [24]. Parathyroid hormone
(produced by the parathyroid gland) causes calcium levels to increase in the blood by
increasing osteoclast activity and proliferation; subsequent bone resorption releases
calcium to the blood [24]. When calcium levels in the blood are too high, calcitonin
(from the thyroid gland) readjusts the balance of mineral resorption and deposition
between osteoclasts and osteoblasts – storing excess blood calcium in the bones [24].

Osteoclasts and osteoblasts are the major cells types involved in the remodeling process,
and they are responsible for bone resorption and formation, respectively [18, 26].
Osteoclasts begin the remodeling process; they arrive at the remodeling site via blood
vessels and resorb bone longitudinally along the diaphysis - forming a long tunnel called
a resorption cone [18]. Osteoclasts must consume large amounts of energy to resorb
bone; to achieve this task, they require an abundance of mitochondria and contain
multiple nuclei [26]. The section of osteoclast membrane involved in resorption is highly
folded, forming many pockets commonly seen in cellular engulfment; this region is
flanked by a clear zone which assists in attachment to the bone and contains no
organelles [26]. As resorption progresses, a capillary advances into the tunnel – it will
eventually become the center of the new osteon [18].

Osteoblasts, on the other hand, have only one nucleus and contain large rough
endoplasmic reticulums – reflective of their role matrix protein synthesis [18]. Before
bone formation can begin, an unmineralized layer, the cement line, coats the walls of the
resorption cone [17, 18]. In the final phases of remodeling, osteoblasts deposit layers of
matrix proteins such as collagen I (col I), osteocalcin (OCN), and osteopontin (OPN)
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which are important for hydroxyapatite (bone mineral) and cell adhesion [18]. The
deposited collagen become mineralized – encasing some osteoblasts in the process [18].
Encased osteoblasts mature to less active osteocytes, and other osteoblasts become bonelining cells or undergo apoptosis; in contrast, all osteoclasts are fated to undergo
apoptosis at the end of the remodeling cycle [18, 26]. Although osteoclasts are
surrounded by mineralized matrix, occupying spaces called lacunae, they are not isolated
[17]. Osteons have several small channels, called canaliculi, passing through the
lamellae through which osteoclast outgrowths form a network [17]. The completed
remodeling process succeeds in repairing minor bone damage over time, but it is not
sufficient for fracture repair in most cases.

Bone Fracture Repair and Critical Size Defects
Even before only 65 years of age, half of Americans will have a bone a fracture [4]. In
these cases, routine remodeling is not sufficient for wound stabilization and healing.
There are two avenues of bone repair processes depending on the conditions of the break:
indirect and direct fracture healing [27, 28]. The former path applies to most breaks
because the fracture does not need to be closely aligned for indirect bone fracture repair
to occur [27, 28].

In the first week post-injury, a hematoma coagulates within and around the fracture; it is
a product of pooled blood, cells, and marrow originating from the bone itself and
surrounding tissue [27, 28]. This phase, known as the inflammatory phase, is
accompanied by the influx of many cell types including mesenchymal stem cells,
lymphocytes, monocytes, and macrophages [28]. Pluripotent cells contribute descendant
bone cells, chondrocytes, and other cells crucial for tissue regeneration; inflammatory
cytokines stimulate angiogenesis [27, 28]. The end of this phase is overlapped by the
start of the reparative phase - which proceeds for about three to six more weeks [28].
Fracture stabilization is the first priority of the reparative phase – relying on
chondrogenesis to create a soft callus to replace the hematoma and penetration of ingrowing blood vessels [27, 28]. Additional stabilization comes early in the reparative
phase when intramembranous ossification produces woven bone in the subperiosteal area
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of the fracture [27, 28]. The soft callus calcifies via endochondral ossification, creating a
hard callus, and blood vessels continue growing into the fracture site [27, 28].
Osteoblasts convert the callus into woven bone by the end of the reparative phase –
connecting the fracture [27, 28]. The final phase of indirect fracture healing remodels the
weaker, woven bone and re-creates the stronger lamellar structures [27]. If the reparative
phase fails to stabilize the wound area or deliver sufficient blood vessels, the fracture
cannot heal – a situation known as a nonunion or critical size defect [27].

Direct fracture healing, of which there are two types, is not as common because it only
occurs for well-aligned fractures with little movement or gap between the broken ends
[27, 28]. For the smallest gaps, less than 0.01 mm, osteoclasts tunnel across the gap and
bridging osteons develop; this process is called contact healing [27, 28]. For gaps less
than ~1 mm, osteoblasts produce lamellar bone to connect the gap, but the layers are
orthogonal to those of the osteons [27]. Like indirect healing, this process - termed gap
healing, requires a remodeling step to restore the osteon structures [27].

In severe fractures, where bone’s self-repair processes are suspected to fail, surgical
intervention is necessary to attempt fracture alignment, stabilization, and in some cases to
replace/regenerate lost bone material with grafts or other materials. A major goal of bone
tissue engineering, and a long-term goal of this research, is to develop bone scaffolds
which can replace these grafts – allowing patient cell ingrowth while degrading away. At
the end of healing, patient tissue would completely replace the scaffold – restoring
function in the bone-loss area.

Markers of Osteogenesis
As hMSCs differentiate towards becoming mature osteoblasts, various genes are
expressed which serve as “markers” of the cell’s osteogenic lineage progression. These
markers include as alkaline phosphatase (ALP), collagen I (col I), osteocalcin (OCN),
osteopontin (OPN), BMP-2, bone sialoprotein (BSP), and runt-related transcription
factor-2 (Runx2) [29]. The expression of the genes, using RNA, can be quantified at
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different time points with a type of reverse transcription polymerase chain reaction
(qPCR).

Commitment of MSCs towards the osteoblastic lineage does not necessarily trigger the
end of proliferation; Runx2 indicates MSC conversion to immature osteoprogenitors –
occurring during the proliferative phase and before the expression of any other markers
[15, 29]. Col I and ALP are also expressed before proliferation ceases; they mark the
maturation of committed osteoprogenitors. Col I is a matrix protein which will become
mineralized at later stages; ALP provides phosphate to bone cells for incorporation into
the ECM [15, 29]. Just before maturation into osteoblasts, preosteoblasts exhibit
decreased proliferation and greatly upregulate BSP [29]. Fully mature osteoblasts have
ceased proliferation and are assigned to bone formation, becoming embedded osteocytes,
or becoming bone-lining cells [18, 26, 29]. Upregulation of OPN, which aids in cell
attachment to mineralized surfaces, is characteristic of this phase [29]. OCN is also only
expressed by mature osteoblasts and is sometimes used as a marker for osteocytes [29,
30].

Biodegradable and Biocompatible Polymers
First generation biomaterials for orthopedic applications were primarily selected to match
or exceed the mechanical properties (elastic modulus, failure stress, etc.) of bone in an
attempt to prevent failure due to everyday compressive, tensile, and torsional stresses
[31]. Stainless steel, Co – Cr alloys, titanium alloys, ultra high molecular weight
polyethylene (UHMWPE), and others have been chosen as implant materials – but nearly
all were bioinert, non-degradable, and intended to be permanent fixtures [31, 32].
Ultimately, these implants were plagued with incidents of aseptic loosening and
osteolysis [33].

Failure was explained by several mechanisms related to mechanical and nondegradable
material properties. First, shear forces on the implant, as seen with hip joints made with
cobalt-chrome-molybdenum alloy or UHMWPE, produced wear debris and particles [33,
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34]. Since the material does not degrade, particles remain around the implant and induce
an inflammatory response; macrophages and fibroblasts encase the implant in soft tissue
and secrete factors linked to osteolysis [33]. On top of inducing an inflammatory
response, particles in the implant site are abrasive and beget additional wear [34].

A difference in mechanical properties between bone tissue and the implant material will
also affect implant loosening. The elastic modulus of cortical bone is about 20-30 GPa
whereas the modulus of metals can be ten times larger [31]. Consequently, these implant
materials shield surrounding bone from everyday stresses; without appropriate stresses,
bone remodeling processes trigger resorption - loosening the implant over time [35].

Degradable biomaterials in orthopedic applications may avoid challenges associated with
stress shielding and wear particles. Additionally, the use of biodegradable materials,
instead of biostable materials, eliminates the need for potential implant removal and
replacement. In biostable materials, wear particles from degradable implants break
down, stresses shielded by the implant unload to the bone as the material degrades, and
the implant may act as a substrate for drug delivery [36]. Degradable polymers already in
commercial use include poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lacticco-glycolic acid) (PLGA), polycaprolactone (PCL), polydioxanone (PDO), chitosan, and
others [37, 38]; these polymers degrade enzymatically or hydrolytically and release nontoxic degradation products [36, 39].

PLA and PGA are aliphatic, synthetic polyesters. When PLA is synthesized only with Llactic acid monomers (PLLA), it can form highly ordered chain arrangements - becoming
approximately 37% crystalline [37]. PGA, a homopolymer, is likewise crystalline –
about 50% [36, 37, 40]. When the D-lactic acid monomer is included in PLA synthesis
(PDLA), it disrupts the organized structure seen in PLLA – creating an amorphous
polymer [37]. The copolymer, PLGA, is commonly synthesized in various lactic acid to
glycolic acid ratios which also modulates the polymer crystallinity – affecting mechanical
properties, degradation rates, glass transition temperature (Tg), and melting temperature
(Tm) [40].
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Polymer chains in a crystalline arrangement are tightly packed; this arrangement restricts
movement during deformation and slows degradation by obstructing water molecule
infiltration [36]. When PLGA’s lactic acid to glycolic acid ratio is below 30:70 or above
75:25, it is at least partially crystalline [40]. On the extremes of this relationship, pure
PGA and PLA have half-lives around five months and seven months, respectively; at a
lactic acid to glycolic acid ratio of 50:50, PLGA half-life is one month or less [37]. As
degradation progresses, non-toxic lactic acid and glycolic acid monomers are
metabolized or eliminated in the urine [37].

In general, crystalline polymers also have a

higher elastic modulus; the modulus of PGA and PLGA is 7 GPa and ~2 GPA,
respectively [37]. Ultimately, a major benefit of PLGA is its tunable properties which
accommodate the implant function. Slower degradation rates may be suitable for bone
injury support whereas shorter half-lives are useful for drug release.

Degree of crystallinity also affects polymer thermal properties. Tm increases with
crystallinity. It is around 225oC and 180oC for pure PGA and PLA, respectively; in
PLGA, it decreases to about 110oC with 20% glycolic acid content [40]. Tg, on the other
hand in relatively unaffected by monomer ratio. It remains around 60oC and drops
slightly with very high glycolide content [40]. Since Tg is above body temperature, these
polymers will not change to a rubbery state when implanted – ensuring reliable
mechanical properties for load-bearing applications. PLGA is currently used in the form
of screws, sutures, and plates for orthopedic applications [37].

Other common degradable synthetic polymers include polycaprolactone (PCL) and
polydioxanone (PDO). Unlike PLA, PGA, and PLGA these polymers have glass
transition temperature equal to or below 0oC [36, 37]. PCL is commonly copolymerized
with other monomers; PDO is used for absorbable pins and sutures [37].

Chitosan is another material used for sutures and is being researched for broader use in
orthopedics [39]. Unlike the aforementioned polymers, chitosan is a naturally derived
polysaccharide. It is made from chitin, a polymer found in crustacean shells, which has
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been deacetylated in a strong alkali solution [38]. Without deacetylation, chitin is not
soluble; when the degree of deacetylation is greater than 30%, chitosan can dissolve in
acidic aqueous solutions and processed/formed for different applications [39, 41].
Chitosan’s degree of deacetylation, which can range from 30%-95%, greatly influences
its crystallinity. Higher levels of deacetylation create monomer homogeneity –
increasing chain organization and, ultimately, degradation rate [41]. Chitosan, with a
high degree of deacetylation, takes months to degrade in the body – producing non-toxic
amino sugars [38]. Despite these properties, chitosan’s mechanical properties disqualify
its use in load-bearing applications, but it is very commonly used as in wound-healing
applications [38, 41].

Osteoinductive and Bioactive Materials
If a material is osteoinductive, it can trigger bone formation via recruitment and
differentiation of progenitor cells towards the osteoblast lineage. In bone graft materials,
this property is almost exclusive to autografts; bone graft substitutes have limited or no
osteoinductive properties without the use of added BMPs [2, 32]. Ideally, materials used
to stabilize fractures or replace/regenerate bone would also bond with bone in the wound
site – a property termed bioactivity [2]. Materials that cannot integrate with bone after
implantation become surrounded with fibrous tissue; they are bioinert [22, 32].

The ultimate test of a material’s bioactivity is its bone-bonding performance in the body;
however, a prediction of material bioactivity can be done in vitro by submerging samples
in simulated body fluid (SBF) or a modified simulated body fluid (mSBF) for several
weeks, then observing the nature of mineral deposition on the material’s surface [22].
SBF, of which there are several versions, imitates the ion concentrations and pH present
in human blood plasma [22]. Most bioactive materials form an apatite layer under these
conditions; when in the body, the mineral layer will develop and integrate with
surrounding bone – forming a bond [22]. MSBFs typically contain greater ion
concentrations than blood plasma and can nucleate submerged materials in less time than
SBFs. Bioactivity is attributed to many organic and inorganic materials such as collagen,
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demineralized bone matrix, calcium carbonate, calcium sulfate, and bioactive glasses [13,
32].

Several bioactive ceramic materials, including certain bioactive glasses, hydroxyapatite,
tricalcium phosphate, and biphasic calcium phosphate, also demonstrate osteoinductive
properties [3, 4, 11, 42-45]. Some researchers have attributed these properties only to the
topography of the ceramics following their reaction with body fluid. Cells, including
osteoprogenitor and human mesenchymal stem cells (hMSCs), use focal adhesion
proteins to attach to the surrounding environment, transmit forces across the
cytoskeleton, and regulate gene expression via the mechanotransduction pathway [46].
Topographical features, such as nanopits or nanofibers, have demonstrated potential to
promote osteogenic differentiation via this pathway; therefore, it is theorized that the
surface features of mineralized materials are a primary factor in promoting osteogenic
differentiation [30, 47].

Alternatively, there is some evidence that calcium and phosphate ions, which are released
as these materials degrade, act as simple signaling molecules – directly interacting with
cells to stimulate osteogenic differentiation [3, 43, 48]. Small molecule induction effects
are already known to occur in other differentiation processes; H 2 O 2 and H 2 S, for
example, stimulate angiogenesis and neurogenesis, respectively [3]. Chai et al. tested
ion-induced osteogenesis in vitro with human periosteum-derived cells cultured in
calcium and phosphate supplemented media; they measured increased osteogenic gene
expression (OCN, OPN, BMP-2, Runx2) in several supplemented media compared to
typical growth medium and osteogenic medium treatments [48]. It is thought that
calcium ions, entering MSCs through ion channels, can activate protein kinase C and
trigger the ERK1/2 pathway; this pathway upregulates transcription factors needed for
BMP-2 activation [3, 49]. Materials that release these ions could be an attractive
alternative to exogenous BMP use.
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Composites
Unfortunately, bioactive glasses are brittle; they do not have the mechanical integrity to
function as graft substitutes on their own. They are frequently made into composites with
biodegradable, biocompatible polymers - such as PLGA, polyphosphazenes, chitosan, or
gelatin - which provide more suitable mechanical properties while releasing the glass
over time [30, 50-53]. Interestingly, bone itself is also a composite of organic and
inorganic components – collagen and hydroxyapatite [16].

A number of composite microsphere bone scaffolds, incorporating 45S5 bioactive glass
[54], nanodiamond particles [55], and carbon nanotubes [56] have demonstrated
mechanical properties in the range of trabecular bone. These studies provided some
indication that a composite scaffold, made with PLGA and the novel BSG, would
perform suitably.

Microsphere Scaffolds
The limits of existing bone graft treatments necessitate the development of an osteogenic,
osteoconductive, bioactive, biocompatible, and mechanically compatible, degradable
bone graft substitute. Polymeric microsphere bone scaffolds have repeatedly
demonstrated a number of these qualities and are common in bone tissue engineering
research and scaffold development [30, 50, 52, 54, 57]. For example, Globus Medical,
Inc. has utilized degradable polymeric microspheres in their Microfuse bone void fillers.

Microsphere fabrication involves an emulsion evaporation technique. Briefly, a polymer
(e.g. PLGA) is dissolved in an organic solvent (e.g. dichloromethane), then poured forming a thin stream - into a stirred aqueous solution of 1% poly(vinyl alcohol) (PVA).
In this case, PVA is used as a surfactant to prevent polymer/solvent droplets from
amalgamating. After several hours of stirring, the organic solvent evaporates and leaves
only polymer microspheres. The microspheres must be washed several times to remove
residual PVA, then dried in a Buchner funnel; they can be sieved to a certain diameter at
this step. They must be completely dried (e.g. using a lyophilizer, vacuum oven, or
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desiccator) before the sintering step. Microsphere diameters can be controlled and
optimized by selecting polymers of different molecular weights or modulating the
concentration of polymer in the organic solvent. The stirring speed should be optimized
to prevent droplets falling out of suspension, or amalgamating, before solvent
evaporation.

Microspheres can be sintered together in a mold to make bone scaffolds of varying
dimensions. To achieve bonds between microspheres, the mold must be heated above the
polymer Tg long enough for the polymer chains in neighboring spheres to intertwine.
Upon cooling, these chains remain entangled – attached the spheres to each other. The
mold temperature and heating time can be optimized to modulate pore size and
compressive modulus [57].

Microsphere scaffolds have interconnecting pores which can be designed large enough to
allow cell infiltration and migration. In the case of hMSCs, pore diameter should be
about 100-250 μm – about ten times the diameter of the cell; Borden et al. showed that
microspheres with a diameter > 250 μm could achieve a large number of pores in this
range [57]. Overall scaffold porosity influences the final matrix porosity of the
regenerating tissue – where host tissue grows develops the inverse porosity of the
scaffold after growing into the void spaces [57]. In other words, when designing a bone
scaffold for trabecular bone, which is 70% porous, the ideal scaffold porosity would be
~30% [57]. When made from a biocompatible and degradable polymer, microsphere
scaffolds can meet many of the ideal bone scaffold criteria. The polymer can be
combined with osteoinductive and bioactive materials to form a composite –
synergistically combining the polymer mechanical properties with those of the included
material.
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3. MATERIALS AND METHODS

Materials
Scaffolds were made from a composite of 50:50 PLGA and BSG. 50:50 PLGA (product
5050 DLG 7E; Mw = 106 kDa; Mn = 64 kDa; Tg = 47.9° C) was obtained from
Lakeshore Biomaterials (now Evonik Industries). The BSG was fabricated in
collaboration with Dr. Dong Qiu’s lab at the Chinese Academy of Sciences. It was
comprised of 10.8 mol% P 2 O 5 , 54.2 mol% SiO 2 , and 35 mol% CaO.

Low-glucose DMEM, fetal bovine serum (FBS), L-glutamine, penicillin/streptomycin
(P/S), and phosphate buffered saline (PBS) were obtained from Life Technologies
(Thermo Fisher Scientific). Dexamethasone, β-glycerophosphate, and L-ascorbic acid 2phosphate, were obtained from Sigma-Aldrich. Human mesenchymal stem cells
(hMSCs) were purchased from Lonza.

Composite Microsphere Fabrication
The amount of BSG in the composite was optimized by evaluating the dispersion of the
BSG powder at different levels inside the microspheres with SEM and EDS microscopy
(Quanta 3D FEG from FEI). BSG powder was added as a weight percentage of the
PLGA; levels included 2%, 5%, 10%, 20%, and 40% BSG. Microspheres were formed
using the emulsion/solvent evaporation technique outlined in Deng et al [11]. First, 8%
(w/v) PLGA was placed in a glass vial with dichloromethane (i.e. 1.6g 50:50 PLGA in 20
mL dichloromethane). The vial was secured with a phenolic cap and wrapped with
parafilm, then it was vortex mixed in a fume hood at moderate speed for at least one hour
- until all PLGA powder was dissolved. BSG powder was added to the polymer solution
in the vial; the vial was re-wrapped in parafilm, then placed in a bath sonicator for 30
minutes. The final dispersion was poured, making a thin stream, into two liters of 1%
PVA solution – stirring at 400 RPM. The emulsion was stirred until the dichloromethane
thoroughly evaporated – at least 6 hours. The resulting composite microspheres were
drained from the 1% PVA, rinsed thoroughly in deionized water, dried in a Buchner

17
funnel, then sieved to obtain a diameter range within 250-500 µm. The microspheres
were lyophilized overnight to remove all residual moisture and stored in a desiccator.

Microsphere Sintering
Microspheres were packed into a cylindrical mold (0.5 cm diameter; 1.5 cm long), and
heated in an oven at 90°C for 2 hours. The mold cooled to room temperature before
opening and retrieving the scaffolds. Pure PLGA scaffolds, without any added BSG,
were fabricated as a comparison against the composite.

Scaffold Characterization
3.4.1

Mechanical Testing

Compression testing was performed on an MTS Criterion Model 43 as described in Jiang
et al. [52]. Cylindrical scaffolds were cut to 1 cm in length – achieving a 2:1 length to
diameter ratio. Scaffolds were compressed at a cross head speed of 5 mm/min at
atmospheric conditions. The length and diameter of each compressed scaffold was
measured with calipers before compression; these measurements were used for
converting force and change-in-length to stress and strain, respectively. The linear
regions of the resulting stress versus strain charts were fit with regression lines - where
the slopes were the elastic moduli of each compression. The elastic modulus of both
scaffold types was averaged from n=7 compressions.
3.4.2

Porosity

Initial scaffold imaging was done in a Skyscan 1172 (Bruker) micro computed
tomography (μCT) scanner at the Indiana University School of Medicine in Indianapolis,
IN. The bioactive glass material was differentiated from the PLGA a greater radiopacity
than PLGA; thresholding was used to locate the BSG material within the composite.
Further porosity analysis was done on a Quantum GX μCT (PerkinElmer) – which was
installed at Purdue’s Bindley Imaging Facility in Summer/Fall 2017 (n=1 due to material
constraints). Each scaffold was scanned at 90 kV and 88 μA - using a 36mm field of
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view (FOV) for 14 min (high-resolution scan settings). From this, 12.23 mm3 subvolumes of the scaffolds were reconstructed with a voxel size of 4.5 μm. A median filter
was applied to each scan using a kernel size = 5. Scaffold material and air were
differentiated using thresholding tools, and the volumes of each were calculated in the
region of interest tool. Percent porosity was calculated as [(volume of air)/(total
volume)] x 100.
3.4.3

Biomimetic Studies

3.4.3.1 Modified Simulated Body Fluid
Table 1: Order and concentrations of added reagents in mSBF preparation.
Concentration

Order

Reagent

1

NaCl

141

2

KCl

4

3

MgSO 4

0.5

4

MgCl 2

1

5

NaHCO 3

4.2

6

1M HCl

*

7

CaCl 2

5

8

KH 2 PO 4

2

9

Tris

20

(mM)

*Add ~39 mL per 1L mSBF; pH should be
2.0 +/- 1.0 following this step [22]

Scaffolds were evaluated for bioactivity in vitro by submersion in modified simulated
body fluid (mSBF) for two weeks. MSBF, containing twice the calcium (5mM) and
phosphate (2mM) concentrations of body fluid, was prepared based on the procedure in
Kokubo et al. [22]. Briefly, a clean, scratch-free beaker was rinsed, filled with 700 mL
Milli-Q water, and heated to 37oC. The first 5 reagents were added in the order indicated
in Table 1 – allowing each to dissolve completely before adding the next. Prior to CaCl 2
addition, 1 M HCl was incorporated until pH dropped to 2.0 +/- 1.0; the solution was
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monitored for any precipitates or cloudiness. CaCl 2 and KH 2 PO 4 were also added
slowly and sequentially until dissolved. The final reagent, Tris buffer, was added a few
granules at a time – slowly elevating the solution pH, but keeping it below 6.8. Any
cloudiness was dissipated with the immediate addition of 1 M HCl. Additional Tris was
added, as needed, to bring the final pH back up to 6.8.

The beaker was covered and allowed to cool to room temperature before adding
additional Mill-Q water – making a total of 1000 mL mSBF solution at room
temperature. Before using a clean plastic flask to store the solution, the flask was rinsed
three time with a portion of the mSBF. The storage flask was kept at 4oC.
3.4.3.2 Scaffold Treatment and Analysis
MSBF was aliquoted into several plastic tubes, placing 5 mL per tube, then warmed in a
water bath to 37oC. Scaffolds were submerged in mSBF, one scaffold per tube, and
incubated at 37oC for a period of two weeks. The mSBF was changed daily. Upon
retrieval at days 7 and 14, scaffolds were rinsed three times in deionized water and dried
in a lyophilizer.

Low-vacuum EDS (Quanta 3D FEG from FEI), at 0.68 torr, was utilized to measure the
composition of the apatite on the scaffolds. Samples were not coated. The energy range
was set at 10 keV; data was collected for three frames, with process time set to three, and
dwell at 300 μsec per pixel (resolution = 512).
High vacuum SEM of platinum-coated samples captured the apatite’s morphology. Prior
to imaging, samples were coated for 60 seconds with a 208HR sputter coater
(Cressington) set to 40mA. The sample stage was tilted 45 degrees and rotated during the
coating deposition to cover the entirety of the samples’ surfaces. Mineralized surfaces of
the composite scaffolds were compared to those of pure PLGA.
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In Vitro Studies
Cylindrical scaffolds were cut into three, equal-length pieces (0.5 cm length and 0.5 cm
diameter per piece). A large sample, n = 25, of cut scaffolds was weighed, and the
distribution of weights was analyzed for normality. An acceptable weight range for
composite and pure PLGA scaffolds was established as the mean weight +/- two standard
deviations – removing scaffolds outside this range to reduce variability. Prior to cell
culture, cut scaffolds were sterilized by immersion in 70% ethanol for 10 minutes, rinsed
in sterile water, and exposed to UV light - periodically rotating scaffolds and ensuring at
least 30 min exposure per side [52].

HMSCs were expanded in growth medium (88% low glucose DMEM, 10% FBS, 1% Lglutamine, 1% P/S) until passage four. 50,000 hMSCs were seeded per scaffold in a 48well plate, then cultured in 500 μL osteogenic medium (growth medium with 10 nM
dexamethasone, 20 mM β-glycerophosphate, 50 μM L-ascorbic acid 2-phosphate) for
three weeks. Osteogenic medium was changed every third day. During both cell
expansion and scaffold maintenance, the incubator was kept at 37°C and 5% CO2.
3.5.1

Cell Viability

At days 1 and 3, live-dead (EthD-1 and Calcein AM) fluorescent assays were performed
on a Nikon A1R MP confocal microscope. At each time point, the medium was removed
from the wells, and scaffolds were rinsed with PBS two times. EthD-1 and Calcein AM
were combined in PBS to achieve 4 μM and 2 μM concentrations, respectively. A 5:2
volumetric ratio of PBS and the dye mix was added to each well and incubated for 30
minutes at room temperature; scaffolds were transferred to a glass-bottom confocal dish
and covered with anti-fade medium before z-stack imaging at 0.8 μM depth increments.
Live and dead cells fluoresced green and red respectively. Control scaffolds, without
cells, were examined to determine the presence of background fluorescence from the
scaffold material.
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3.5.2

Cell Morphology and Scaffold Coverage

At two and three-week time points, scaffold cell coverage and hMSC morphology were
evaluated with nuclei and actin cytoskeleton staining. In preparation for the staining,
cell-covered scaffolds were washed with PBS and moved into clean wells; fixation with
4% paraformaldehyde was applied for 20 minutes. Fixed scaffolds were washed twice on
a plate rocker - 5 minutes in PBS per wash. 0.1% TritonX-100 solution was applied for 5
minutes to permeabilize cell membranes; it was followed by another two washes in PBS.
Blocking solution was applied for 30 minutes to prevent non-specific staining – followed
by another two PBS washes. A dye solution containing a 1/1000 dilution of Hoechst
33342 (Life Technologies) and a 1/1000 dilution of TRITC-conjugated phalloidin
(Millipore) was prepared in PBS. The scaffolds were submerged in this solution for 20
minutes; each scaffold was washed in PBS three times, transferred to a glass-bottom dish,
and covered with anti-fade medium before confocal imaging at 0.8 μM depth increments.
ECM deposition and cell-covered scaffold topography were also examined at two and
three-week times points with SEM (Quanta 3D FEG from FEI). At each time point, cellcovered scaffolds were washed with PBS and moved into clean wells. Samples were
fixed in 4% paraformaldehyde for 1 hour at room temperature, then placed at 4oC another
24 hours. Scaffolds were washed with PBS twice, as described above, then dehydrated in
a series of ethanol dilutions (50%, 70%, 80%, 90%, 95%, then 100%) for 10 minutes
each. Following the final ethanol solution, scaffolds were left to dry; they were stored in
a desiccator until ready for imaging. Prior to high-vacuum SEM imaging (Quanta 3D
FEG from FEI), samples were coated in platinum for 60 seconds with a 208HR sputter
coater (Cressington) set to 40mA. The sample stage was tilted 45 degrees and rotated
during the coating deposition.
3.5.3

Cell Proliferation

Proliferation was quantified using the Quant-iT PicoGreen dsDNA Assay Kit from
Invitrogen (Thermo Fisher Scientific). Both composite and pure PLGA scaffolds (n=4)
were cultured as described earlier - along with acellular scaffolds as a control. At weekly
time points, scaffolds were washed with PBS twice, moved to new wells, covered in 500

22
μL 1% Triton X-100, and frozen at -80° C. After three freeze/thaw cycles, the lysed cell
solution in each well was measured for DNA concentration.

Briefly, cell lysates were four-fold diluted in TE buffer, then combined with the Pico
Green fluorescent reagent - volumetrically 1:1. After incubating in darkness for five
minutes at room temperature, the solutions were transferred to a 96-well flat bottom
plate. They were measured for fluorescence in a Synergy H1 microplate reader (BioTek
Instruments) set for excitation at 485 nm and reading at 535 nm emission. Fluorescence
from acellular scaffolds was subtracted from sample fluorescence to eliminate
background fluorescence. A standard curve was generated, from which sample DNA
concentration could be derived, using a range of known DNA concentrations.
3.5.4

Osteogenic Differentiation

3.5.4.1 Alkaline Phosphatase Activity
A colorimetric alkaline phosphatase (ALP) activity assay (Bio-Rad Laboratories) was
used as a metric for the extent of hMSC osteogenic differentiation. Cell lysates from the
same wells as the Quant-iT PicoGreen assay (n=4 with an acellular control) were
sampled for this assay.

P-nitrophenyl-phosphate (pNPP) tablets were dissolved in diethanolamine buffer (one 5
mg tablet per 5 mL buffer). 100 μL of each sample lysate was combined with 400 μL
pNPP solution in a new well plate. Plate incubation at 37oC for 30 minutes allowed the
ALP enzyme to dephosphorylate the pNPP reagent – resulting in a yellow color change.
The dephosphorylating reaction was stopped using 500 μL of 0.4N NaOH, and samples
were subsequently evaluated in a Synergy H1 microplate reader (BioTek Instruments) for
absorbance at 405 nm. Baseline absorbance values, from acellular controls, were
subtracted from the samples’ absorbance values. These corrected absorbance values were
normalized to the DNA concentration measured from the same scaffold. Normalized
absorbance was compared between pure PLGA and composite scaffolds – where greater
absorbance was associated with greater ALP activity.
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3.5.4.2 Alizarin Red Staining
Alizarin red staining of cell-covered scaffold mineralization also monitored osteogenic
differentiation at two and three-week time points. Cells were seeded onto composite and
pure PLGA scaffolds (n=4 with an acellular control) as described previously. At each
time point, the cultured scaffolds were washed with water and moved to clean wells
before fixation in 70% ethanol for 1 hour at 4oC. Samples were washed with water for 5
minutes on a plate rocker, then covered in a 40 mM alizarin red solution (pH=4.23) for 10
minutes. The excess dye was removed in five washes – using 500 μL water for five
minutes each. To dissolve the remaining, adhered dye, a 10% (w/v) cetylpyridinium
chloride (CPC) solution was prepared in 10 mM Na 2 HPO 4 and adjusted to a pH of 7.0.
Washed scaffolds were submerged in 500 μL CPC for 24 hours. The concentration of the
dissolved alizarin red dye was quantified as absorbance at 562 nm in a Synergy H1
microplate reader (BioTek Instruments). Baseline absorbance values, from acellular
controls, were subtracted from the samples’ absorbance values. Absorbance values were
averaged and normalized to DNA concentration at the same time point.
3.5.4.3 Gene Expression
Real time PCR was used to evaluate gene expression of several early and late-stage
markers of bone formation. Expression of alkaline phosphatase (ALP), bone
morphogenetic protein-2 (BMP-2), runt-related transcription factor-2 (Runx2), and
osteocalcin (OCN) was measured against the expression of the housekeeping gene, 18S.
ALP, an early osteogenic marker, is active throughout bone-formation and is key to
mineralization – providing phosphate for calcification [15]. BMP-2, as discussed earlier,
is an osteoinductive protein produced during osteogenesis.

At two and three week time points, cell-covered scaffolds were submerged in Trizol to
remove and suspend all cellular components. The Trizol solution of three scaffolds was
combined to produce one sample in a 1.5 mL tube; there were three samples (n = 3) for
each scaffold type. RNA was separated from other components using 200 μL of cold
chloroform – which was added to the samples and vigorously shaken. The samples sat at
room temperature for three minutes before centrifugation at 14,000 RPM for 20 minutes
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at 4oC. The resulting supernatant was carefully transferred into new 1.5 mL tube, and an
equal volume of cold isopropanol was added and gently agitated to precipitate the RNA.
The samples rested for 10 min before centrifugation at 14,000 RPM for 20 minutes at
4oC. The resulting pelletized RNA was rinsed in 4oC 75% ethanol, then in 4oC 100%
ethanol – centrifuging at 8,000 RPM for eight minutes after each wash. The washed
pellets were diluted with 30 μL RNAse free water and stored at -80 oC.
Prior to complementary DNA (cDNA) synthesis, RNA concentration of the samples was
measured using a NanoDrop Spectrophotometer (Thermo Scientific). 700 ng of RNA for
each sample was converted to cDNA. Briefly, 700 ng RNA of each sample was diluted
to a total volume of 10 μL. This was combined in PCR tubes with 2 μL of a mixture of
deoxynucleotides (dNTPs) and random hexamers (Invitrogen). After 5 minutes at 65oC
in a thermal cycler, a second solution containing dithiothreitol (DTT), a 5x buffer, and
reverse transcriptase (Invitrogen) was added. In the thermal cycler, the PCR tubes
continued for 10 minutes at 25oC, 50 minutes at 37oC, 15 minutes at 70oC, then down to
4oC prior to removal. CDNA was stored at -20oC until assayed with quantitative
polymerase chain reaction (qPCR).

Following cDNA synthesis, target genes were amplified using the LightCycler 96
Instrument (Roche). The relative amount of each target gene was normalized against the
expression of 18S using a comparative CT method [58]. The primers for these genes are
as follows: ALP 5’-ACTGGTACTCAGACAACGAGAT-3’ (forward) and 5’ACGTCAATGTCCCTGATGTTATG-3’ (reverse); BMP-2 5’ACTACCAGAAACGAGTGGGAA -3’ (forward) and 5’GCATCTGTTCTCGGAAAACCT -3’ (reverse); Runx2 5’CCGCCTCAGTGATTTAGGGC-3’ (forward) and 5’GGGTCTGTAATCTGACTCTGTCC-3’ (reverse).

Statistical Analysis
All quantitative data were reported as mean ± standard deviation. Statistical analysis was
performed in Minitab software (Minitab Inc.) to determine the existence of outliers and
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statistical differences. Outliers were explored using the Dixon’s Q test and interquartile
range (IQR) methods; all outliers are identified alongside the results. Differences between
two means were determined using a two-sided t-test – assuming unequal sample
variances.
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4. RESULTS AND DISCUSSION

Optimization of Bioactive Silicate Glass Content

Figure 1: Composite microsphere and scaffold fabrication. (a) 8% (w/v) PLGA was
dissolved in dichloromethane; BSG powder was combined into the polymer solution. (b)
The composite dispersion was poured as a thin stream into two liters of 1% PVA. (c)
Once the solvent evaporated, the resulting microspheres were rinsed, dried, and sieved to
proper diameter. (d) Thoroughly lyophilized microspheres were packed into a mold and
sintered. (e) Composite scaffolds were removed from the mold after cooling.
Scaffolds were constructed as outlined in the methods section. Briefly, BSG powder was
dispersed in dissolved 50:50 PLGA (Fig. 1a). Microspheres were fabricated with
different levels of BSG content: 2%, 5%, 10%, 20%, and 40% by weight of the PLGA.
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The dispersion was poured into a 1% PVA solution – using the emulsion/solvent
evaporation technique outlined in Deng et al [11] (Fig. 1b). Spheres were sieved to a
250-500 μm range (Fig. 1c) and lyophilized before sintering in a cylindrical mold (Fig.
1d). Resulting scaffolds (Fig. 1e) were removed once the mold returned to room
temperature.

Figure 2: Low-vacuum SEM micrographs and EDS maps of microsphere interiors
containing different levels of bioactive silicate glass. Microspheres contain (a) 2%, (b)
5%, (c) 10%, (d) 20%, and (e) 40% bioactive silicate glass. Scale bar represents 500 μm.

Microspheres containing various amounts of BSG were bisected and evaluated under
SEM (Fig. 2) and EDS (Fig. 3) for BSG homogeneity. Agglomerations of BSG within
the PLGA were apparent – especially at the highest concentrations. Agglomeration of the
dispersed phase is common in the creation of composites, and it is attributed to charge
differences between the two materials. Prior studies involving composites of
hydroxyapatite dispersed in PLA and PLGA also observed agglomerations – where
hydroxyapatite is hydrophilic in comparison to the polymer [59, 60]. Materials that are
hydrophobic in comparison to the polymer, such as diamond particles, will aggregate as
well [55]. In this study, agglomerations were apparent at high concentrations of BSG
(above 10%) where they reached diameters of >125 μm. Agglomerations could
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Figure 3: Low-vacuum SEM micrographs and EDS maps of microsphere interiors
containing different levels of bioactive silicate glass. Microspheres contain (a) 2%, (b)
5%, (c) 10%, (d) 20%, and (e) 40% bioactive silicate glass. Scale bar represents 250 μm.
contribute to variable ion release and BSG content, and they interfere with sphere-tosphere bond formation. When present near the surface of a microsphere, an
agglomeration can occupy the sphere-to-sphere bond area – preventing polymer in that
area from participating in a bond (Fig. 4). 10% BSG was the highest concentration of
ceramic that could be added before large agglomerations formed.

Scaffold Characterization
4.2.1

Mechanical Testing

Compression testing of both scaffold types revealed a triphasic stress vs strain
relationship [61]. An initial phase of elastic deformation was followed by a phase of
inelastic compression - where applied stress remained nearly constant during continued
deformation. No failure point was reached; instead, once the scaffolds’ pores collapsed
in the inelastic phase, increased stress was required for further deformation. This final
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Figure 4: SEM micrographs of sintered microspheres containing different levels of
bioactive silicate glass. Microspheres contain (a) 2%, (b) 5%, (c) 10%, (d) 20%,
and (e) 40% bioactive silicate glass. Arrows show the locations of BSG
agglomerations at the surfaces of the microspheres; these have the potential to
interfere with bond interfaces. Ovals encircle examples of microsphere bonds
where no BSG interference is visible. Scale bar represents 400 μm.
region of increasing stress characterized a third phase in the stress vs. strain curve which
mimics that of trabecular bone. As trabeculae collapse during compression, pore spaces
in the bone are filled – much like the pores collapsing in our microsphere scaffolds [61].
Additionally, the elastic modulus for each scaffold type was in the range of trabecular
bone (20 – 900 MPa) [46, 61]. Still, elastic modulus was lower for the composite
scaffold with 342 ± 42 MPa and 525 ± 68 MPa for composite and pure PLGA,
respectively (one outlier was detected and removed for composite scaffolds). As
discussed earlier, the presence of BSG agglomerations on the composite microspheres’
surfaces may obstruct sphere-to-sphere contact and sintering. Weakened bonds allowed
more deformation per unit of stress and diminished the composite scaffolds’ elastic
modulus.
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4.2.2

Porosity

A Skyscan 1172 microCT was used to examine the distribution of BSG within the
scaffold (Fig. 5). The BSG was highlighted from the rest of the scaffold using
thresholding tools. As expected, BSG appeared homogeneously throughout the scaffold.

Porosities of pure PLGA and composite scaffolds were approximated using the Quantum
GX microCT. Composite scaffold interconnected pores accounted for about 26.6% of the
total scaffold volume. Pure PLGA scaffold pores accounted for about 37.7% of the total
scaffold volume. This was comparable to microsphere scaffold porosities in literature
[50].

Figure 5: Micro-CT cross-section of composite scaffold. 50:50 PLGA is represented in
grey. Bioactive glass is represented in red. The dispersion of bioactive glass is
homogeneous throughout the scaffold.

Overall scaffold porosity influences the final porosity of ingrowing tissue – which
develops an approximate inverse porosity to the scaffold. Since the porosity of trabecular
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bone is ~70%, the scaffold porosity was desired to be around 30%. Both measured
porosities were close to this target.
4.2.3

Biomimetic Studies

Figure 6: (a)-(d) SEM micrographs of apatite morphology on pure PLGA scaffolds
(a,c) and composite scaffolds (b,d) after 7 days (a,b) and 14 days (c,d) in mSBF.
Scale bar represents 200 μm. (e-h), higher magnification SEM micrographs of the
apatite on pure PLGA scaffolds (a, c) and composite scaffolds (b, d) after 7 and 14
days in mSBF. The apatite appears similarly on both scaffold types as plate-like.
Scale bar represents 10 μm.
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Scaffolds were retrieved from mSBF after one and two weeks, and their surfaces were
examined with SEM (Fig. 6) and EDS (Fig. 7) to discern the deposited mineral structure
and composition. Reaction of SBF or mSBF with a material can provide a prediction of
that material’s bioactivity – where acquisition of a calcium phosphate layer indicates the
material may bond to native bone in a defect site.

Figure 7: Corresponding EDS maps of the scaffolds’ surfaces confirmed calcium,
phosphorous, and remaining silicon presence. Scale bar represents 500 μm.
Mineral nucleation initially formed 10-50 μm clusters at day 7 (Fig. 6ab); it covered both
pure PLGA and composite scaffold surfaces by day 14 (Fig. 6cd). Mineral morphology
appeared as randomly oriented plate-like structures, 3-5 μm wide (Fig. 6e-h). EDS
mapping confirmed the layer to consist primarily of calcium phosphate with a 1.5-1.6
calcium to phosphorous ratio (Table 2). This ratio is close to that of hydroxyapatite
(bone mineral) and tricalcium phosphate – 1.67 and 1.5 respectively [62]. Both of these
calcium phosphates are considered bioactive [32].
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Table 2: Composition of apatite on scaffold surfaces after two-week treatment in mSBF.
Elements below 1 atomic% not reported.
Time

Scaffold

Point

Type

Day 7

Pure PLGA

Composite

Day 14

Pure PLGA

Composite

Element Atomic %
O

46

C

42.4

Ca

6.8

P

4.4

O

47.2

C

38.2

Ca

8.6

P

5.4

O

58.7

Ca

17.7

P

11.8

C

10.7

O

58

Ca

18.6

P

12.1

C

9.6

Ratio
Ca:P

1.55

1.59

1.50

1.54

Although pure PLGA is not considered bioactive, it did acquire a mineral layer after
submersion in mSBF for seven days. The mechanism for mineral deposition on PLGA is
well-defined: hydrolyzed PLGA bonds expose hydroxyl and carboxyl functional groups,
these partially negative functional groups attract calcium cations, which sequentially
attract phosphate anions [63]. Many iterations of cation and anion deposition eventually
produce visible mineralization on the polymer surface.
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While mineral deposition did occur on both scaffold types, there were signs of more
homogenous mineral deposition on the composite. Early nucleation on the pure PLGA
scaffold was preferential to rough areas of the scaffold surface –areas which had
contacted the mold during sintering. These regions may have served as nucleation points
for mSBF mineralization. By day 14, mineralization in these regions on the PLGA
scaffolds formed massive clusters almost 200 μm in diameter. Composite scaffolds also
mineralized on rough or sharp areas; however, by day 14 the entire scaffold was covered
in a lawn of apatite-like structures. Discernible clusters were not larger than 100 μm in
diameter – suggesting that mineralization occurred more homogeneously than on pure
PLGA.

According to Li et al., phytic acid-derived bioactive glasses of similar compositions were
capable of mineralizing on their own in SBF novel [14]. Ultimately, the true test of the
scaffolds’ bioactivities would be their ability to bond with native bone in vivo.

In Vitro Studies
4.3.1

HMSC Viability

On day one, a live-dead fluorescent assay examined viable cells within 100 μm thick
sections of each scaffold type (Fig. 8ac). Live hMSCs fluoresced green and elongated
morphology; dead cells had a small, round morphology and fluoresced red. There were
no apparent differences in cell viability between pure PLGA and composite scaffolds.

The hMSCs were attached to the scaffolds and began to bridge gaps between adjacent
microspheres. At day three, viability was evaluated in a 300 μm thick section of each
scaffold (Fig. 8bd); again, there were no apparent viability or morphology differences
between pure PLGA and composite scaffolds; both supported hMSC attachment and
viability.
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Figure 8: Confocal z-stack images of hMSCs on scaffolds. A live/dead fluorescent
assay was performed on days 1 (a,c) and 3 (b,d) to assess cell viability - with green
fluorescence occurring on live cells and red fluorescence on dead cells. Day 1 zstack micrographs span 100 μm depth. Day 3 z-stack micrographs span 300 μm
depth. Scale bar represents 300 μm
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Figure 9: Confocal z-stack images of hMSCs on scaffolds. Hoechst and
TRITC staining at days 14 (a,c) and 21 (b,d) illustrate cell morphology
and spreading. Blue fluorescence shows the location of cell nuclei; red
shows cell actin. Micrographs span 300 μm depth. Scale bar represents
300 μm.

4.3.2

HMSC Morphology and Scaffold Coverage

At days 14 and 21, the cells were more confluent than at earlier time points (Fig. 9a-d).
Cells at day 14 still had an elongated morphology; however, as cell-to-cell contact
increased, individual cytoskeletons could not be discerned. By day 21, extensive scaffold
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coverage made it possible for microsphere shapes to be discerned. This is especially
apparent on pure PLGA scaffolds at day 21 (Fig. 9b).

Figure 10: SEM micrographs of cells and extracellular matrix deposition on pure PLGA
(a,c) and composite (b,d) scaffolds at day 14 (a,b) and day 21 (c,d). White arrows
indicate regions where cellular ECM deposition is apparent. Scale bar represents 200
μm.
Scanning electron micrographs also indicated extensive scaffold coverage at days 14 and
21 (Fig. 10). By day 14, the hMSCs had covered the topmost layer of the scaffold –
observed by changes in scaffold topography and cell bridging between adjacent
microspheres. Without cell coverage, pure PLGA scaffold surfaces appeared smooth
with sharply defined bond regions; composite scaffolds appeared similarly except for
occasional BSG surface agglomerations. By two and three weeks of cell culture, surfaces
and bond regions were masked with cells and ECM components – creating rough,
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irregular surface features and concealing bond areas. Where deeper scaffold layers could
be seen, cell infiltration beyond the topmost layer was apparent.
4.3.3

HMSC Proliferation

Figure 11: DNA concentration as measured by the PicoGreen dsDNA assay.
* p-value < 0.05 ** p-value < 0.01 # one outlier removed
Proliferation was quantified with a PicoGreen assay (Fig. 11) and reported as DNA
concentration per mL. On average, DNA concentration in sample lysates was higher for
pure PLGA scaffolds than composite at days 7, 14, and 21. This difference was
statistically significant at days 14 (p < 0.01) and 21 (p < 0.05). HMSC progression
towards the osteoblast lineage was examined as a potential cause for limited proliferation
on the composite compared to PLGA. As hMSCs differentiate, cell proliferation slows
and eventually ceases [29]; therefore, if hMSCs on the composite are differentiating
quicker versus PLGA, proliferation will cease earlier on composite. ALP activity, ECM
calcification, and osteogenic gene expression was assayed to determine the extent of
osteogenic differentiation on each scaffold type.
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4.3.4

HMSC Osteogenic Differentiation

ALP activity is detectable in early osteogenic differentiation, and ALP expression
increases until osteoblasts begin to embed in bone mineral – becoming osteocytes [29].
ALP activity was assayed to quantify osteogenic differentiation and was reported on a per
cell basis by normalizing absorbance to DNA concentration. On average, normalized
ALP activity was greater on the composite scaffolds at all measured time points, but
these differences were statistically significant only at days 7 and 14 (Fig. 12). Presence
of ALP activity at day 7 signals that osteogenic differentiation is already underway.
Greater ALP activity per cell on composite scaffolds is evidence that the novel BSG has
prompted hMSCs further along the path of differentiation.

Figure 12: Alkaline phosphatase activity at days 7, 14, and 21. Greater activity was
seen on composite scaffolds at days 7 and 14. Error bars represent standard deviation.
*p-value < 0.05
Calcification of cell-deposited ECM is a sign of late-stage differentiation – occurring
after proliferation and initial ECM deposition [29]. Alizarin red stain adhered to calcified
ECM and was qualitatively observed for homogeneity and intensity (Fig. 13). Both
scaffold types appeared to have similar staining intensity, but staining appeared less
homogenous on the pure PLGA scaffolds.

Greater opacity in the composite material
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may have obscured staining below the surface layer of microspheres. Inclusion of BSG
in the polymer imparted opaqueness to the composite – whereas pure PLGA scaffolds
were translucent.

Figure 13: Alizarin red staining of scaffolds with cell-deposited mineralization
after 21 days of hMSC culture. The top row contains (a) pure PLGA scaffolds;
the bottom row contains (b) composite scaffolds. Scaffolds are pictured in a 48well plate.

Figure 14: Quantification of alizarin red staining for calcium deposition
on the scaffolds at days 14 and 21. Error bars represent standard
deviation. * p-value < 0.05 ** p-value < 0.01
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To obtain a true comparison of scaffold mineralization, the quantity of adhered alizarin
stain was assessed. Scaffold stains were dissolved in 10% CPC, and the resultant
solutions measured for absorbance (Fig. 14). Absorbance was normalized to DNA
concentration and reported as ECM calcification on a per cell basis. At day 14, celldeposited mineralization was low, but pure PLGA scaffolds contained slightly more
calcified matrix per cell versus composite (p < 0.05). At day 21, cells on the composite
scaffold had produced substantially more calcified matrix than those on pure PLGA (p <
0.01). Matrix deposition with low mineralization at day 14 aligns with the characteristics
of hMSCs in mid-differentiation; cells have slowed or ceased differentiating, but are not
yet fully mature osteoblasts [29]. By day 21, cells on the composite scaffolds may have
entered late-stage differentiation – marked by extensive ECM calcification. Gene
expression of early and late stage osteogenic markers, using real time PCR, was
compared against this proposed timing.

Figure 15: Real time PCR analysis of osteogenic gene expression
at day 14. * p-value < 0.05
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Real time PCR provided further evidence of hMSC osteogenic differentiation by assaying
expressed genes within the osteogenic pathway (Fig. 15). At day 14, there was a twofold increase in Runx2 expression of cells on the composite scaffold compared to pure
PLGA (p < 0.05). Runx2 is the earliest expressed osteogenic gene; it is an indicator that
the seeded hMSCs have committed to the osteogenic pathway, but it does not reveal the
extent of progress towards becoming mature osteoblasts [29]. ALP expression trended
higher for the composite vs. pure PLGA treatment (four-fold increase in expression; pvalue = 0.061). ALP is expressed by osteoprogenitors, preosteoblasts, and mature
osteoblasts [29]; its expression is indicates the hMSCs are mid-differentiation. Greater
ALP expression on the composite treatment implies greater progression towards
becoming mature osteoblasts. The expression of BMP-2 at day 14 is not significantly
different between scaffold types (three-fold increase in expression; p-value = 0.171), but
it is evidence that the differentiating hMSCs are beginning to approaching full maturation
to osteoblasts [29, 64]. In addition to Runx2, ALP, and BMP-2, OCN was also assayed.
OCN expression for both scaffold types was too low to evaluate when accounting for
noise. OCN is expressed only at the very end of the osteoblast maturation pathway; it
can be even be considered a marker for mineral-embedded osteocytes [29, 30]. At day
14, full maturation is ostensibly not complete, but the quantitative PCR results indicate
that cells on both scaffold types have committed to the osteoblastic lineage; compositeseeded cells are progressing faster.

Based on evidence from the ALP activity, alizarin red, and osteogenic gene assays, it is
evident that hMSCs on the composite scaffolds are differentiating faster than those on
PLGA. Greater differentiation of hMSCs on the composite are evidence of the novel
BSG’s osteoinductive properties. The mechanism of this osteoinductivity is welldocumented for other calcium and phosphate-releasing amorphous ceramics. Cushnie et
al. found that incorporation of hydroxyapatite and PLGA in scaffolds led to elevated
BMP-2 protein expression and osteogenic differentiation of adipose-derived MSCs
compared to PLGA alone [3]. This osteoinductive effect was attributed to the release of
calcium and phosphate ions from the hydroxyapatite – which acted as signaling
molecules to trigger differentiation. Downstream expression of BMP-2 continued to
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drive differentiation via autocrine and paracrine signaling [3]. In this study, the enhanced
osteogenic differentiation of hMSCs the on composite scaffolds further attests to the
osteoinductive potential of calcium and phosphate ions released from BSG.

Conclusions
Composite scaffolds were fabricated from 50:50 PLGA and 10% BSG. The goal of this
study was to determine whether these composite scaffolds would impart greater hMSC
osteogenic differentiation compared to pure PLGA scaffolds while providing suitable
mechanical properties for bone tissue engineering.

Physical measurements of the scaffolds’ porosities and elastic moduli were evaluated and
compared against that of trabecular bone. Imitation of the native tissue’s mechanical
properties is key to providing cellular environmental cues, via the mechanotransduction
pathway, and appropriate load-sharing with in-growing tissue [35, 46]. Compression
testing verified the scaffolds exhibited elastic moduli in the range of trabecular bone and
mimicked trabecular bone’s triphasic compression behavior [61].

In vitro evaluation of the scaffolds’ bioactivity, after submersion in mSBF for two weeks
resulted in mineral deposition on both scaffold types. Mineralization is favorable for
scaffold integration with surrounding bone tissue, but it is not clear to what extent the
novel BSG contributed to scaffold mineralization. In general, the Ca:P ratios of both
mineral layers were near that of tricalcium phosphate and hydroxyapatite – with the ratio
on the composite being a little higher. Future in vivo work could indicate whether these
scaffolds can successfully form bonds with native bone in a wound site.

It was clear from all metrics assessing differentiation that composite scaffolds exhibited
greater osteoinductive properties than pure PLGA scaffolds. Higher levels of ALP
activity, significant at one and two-week time points, marked increased osteogenic
differentiation on composite scaffold. When assayed with qPCR at day 14, expressed
ALP was elevated for composite scaffolds (p-value = 0.061). Runx2 expression was
significantly higher on the composite (p-value < 0.05) - providing strong evidence of
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increased osteogenic differentiation in the presence of the novel BSG. HMSCs on both
scaffold types, at day 14, had likely not reached full maturation as osteoblasts, but
differentiation was underway. At three weeks, cell-deposited scaffold mineralization was
notably greater on the composite (p-value < 0.01). This is evidence of later-stage
osteogenic differentiation and hMSC maturation to osteoblasts.

As hypothesized, the 10% BSG scaffolds delivered appropriate mechanical properties to
for bone tissue engineering applications, and the incorporation of novel BSG imparted
osteoinductive properties to the scaffold. The final scaffold design succeeds in
possessing many ideal properties for the replacement of bone grafts including
osteoconductivity, osteoinductivity, bioactivity, biocompatibility, suitable mechanical
properties, and an appropriate degradation rate.
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5. FUTURE WORK

The summarized work in this thesis focused on using a novel BSG to stimulate
osteogenesis as part of a mechanically competent bone scaffold. Since the novel BSG
has demonstrated ability to impart osteogenic properties to the scaffold, future work will
focus on evaluating this composite scaffold in vivo. Additionally, there are potential
applications for the developed composite material in scaffolds designed for articular
cartilage repair.

The scaffolds developed in this work are currently being studied in vivo in a rabbit
femoral defect model. The in vivo work, conducted in collaboration with Dr. Dong Qiu’s
lab at the Chinese Academy of Sciences, has some initial promising results. The
composite scaffold treatment demonstrated the greatest radiopacity in the defect site after
three months – compared to pure PLGA or control (no scaffold). Also after three
months, defect sites treated with a composite scaffold formed trabeculae-like bone
structures – as seen with micro-CT. Defects treated with pure PLGA did not show these
structures. Histology results for this study are forthcoming.

Additionally, incorporation of the composite material into a scaffold appropriate for
complex tissues and tissue interface repair presents some potential prototyping and
optimization challenges. Future work with 3D printing may allow for quick prototyping
and optimization of biphasic scaffold appropriate for this application. The combination
of 3D printing technology allows for a variety of novel scaffold structures such as those
created by Shi et al. for the treatment of articular cartilage defects [65]. Shi et al. used
fused deposition modeling, a 3D printing technology, to create unique molds for silkfibroin and gelatin scaffolds [65]. Lee et al. used another 3D printing technology,
stereolithography, to encapsulate BMP-loaded microspheres within the scaffold material
[66]. The advent of 3D printing enables researchers to quickly and consistently
manufacture other 3D porous structures besides those conventionally made with
microspheres and foams.
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Although polymers available for 3D printing are somewhat limited, PLA is a commonly
available option. The similar glass transition temperatures of PLA and PLGA make it
possible for these materials to be sintered together post-printing – integrating
osteoinductive and bioactive properties with 3D printed parts. Future work will focus on
incorporating the novel bioactive silicate glass into 3D-printed structures to for treatment
of osteochondral defects.
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